Best MOTS-c Peptide Suppliers 2026: COAs & Third-Party Tests

MOTS-c supplier evaluation diagram showing the 16-residue MRWQEMGYIFYPRKLR sequence inside a mitochondrion with oxidation-prone methionine and tryptophan residues highlighted, beside a lot-specific certificate of analysis

The three oxidation-prone residues in MOTS-c are why a purity percentage alone cannot tell you what is in the vial.

Search “best MOTS-c peptide suppliers” and the first page is almost entirely written by companies that sell MOTS-c, or by affiliates paid when you buy it. Peptides Exchange sells it too, which is precisely why this guide publishes a verification method rather than a ranking.

That is not only an editorial preference. The Federal Trade Commission’s Rule on the Use of Consumer Reviews and Testimonials, 16 CFR Part 465, effective October 2024, prohibits fake and misattributed reviews, undisclosed insider reviews, and company-controlled websites that present themselves as independent reviewers of their own product category. A “top 10 MOTS-c vendors” page operated by a MOTS-c vendor is the kind of content § 465.6 was written for.

There is also a practical problem with rankings here. You cannot run comparative analytical chemistry on six vendors’ material before buying it. What you can assess is how checkable each supplier’s documentation is — and for MOTS-c specifically, there is one chemical property that makes that assessment unusually concrete.

New to this material? Start with What Are Research Peptides? and Peptide Certificate of Analysis: How to Read a COA. For the compound’s background, see What is MOTS-c?.

What MOTS-c is, chemically

MOTS-c — Mitochondrial Open reading frame of the Twelve S rRNA type-c — is a 16-residue peptide encoded not in nuclear DNA but within the mitochondrial genome, in a short open reading frame inside the MT-RNR1 (12S rRNA) gene. It was identified by Changhan Lee and colleagues in Pinchas Cohen’s laboratory at USC and reported in Cell Metabolism in 2015.

The name describes where the coding sequence sits in the mitochondrial genome. It is not an assay, a test kit, or an acronym for a laboratory method — a point worth holding onto when you start searching for suppliers.

Property	Value
Sequence	MRWQEMGYIFYPRKLR
Length	16 amino acids
Molecular formula	C₁₀₁H₁₅₂N₂₈O₂₂S₂
Average molecular weight	≈ 2174.6 g/mol
CAS number	1627580-64-6
Encoded by	MT-RNR1 (12S rRNA) open reading frame, mitochondrial genome
Peptide class	Mitochondrial-derived peptide (MDP)
FDA approval status	None

Sources: PubChem and the primary literature cited below.

Read that sequence carefully, because it is the whole basis of the verification method that follows:

M-R-W-Q-E-M-G-Y-I-F-Y-P-R-K-L-R

Two methionines, at positions 1 and 6, and one tryptophan at position 3. Three oxidation-susceptible residues in a sixteen-residue chain.

Why MOTS-c supplier evaluation is different

Most peptide verification guides tell you to check identity, purity, and content. That advice applies here. But MOTS-c has a failure mode that most peptides in this market do not share to the same degree, and it is the single most useful thing to understand before you read anyone’s certificate.

Methionine and tryptophan oxidize readily. Exposure to atmospheric oxygen, light, trace metal ions, or peroxide impurities in excipients converts methionine to methionine sulfoxide and oxidizes tryptophan to a range of products. Each oxygen addition increases the molecular mass by approximately 16 Da. With three susceptible residues, a single lot can contain the intended peptide alongside mono-oxidized species at ≈ 2190 Da, di-oxidized at ≈ 2206 Da, and so on.

This matters for three reasons that bear directly on supplier choice:

Oxidized species are chemically distinct molecules. They are not “slightly degraded MOTS-c.” They have different masses, and in general oxidized peptides elute earlier than the parent peptide on reverse-phase HPLC because the added oxygen increases polarity.

They can hide inside a good-looking purity number. If an oxidized peak elutes close to the main peak and the integration method merges them, a certificate can report high purity for a sample that is a mixture. This is not usually fraud; it is an integration decision. But it means the number alone does not settle the question.

Doping-control chemists already treat them as separate analytes. When Knoop, Thomas, and Thevis built an LC-MS method for MOTS-c in plasma (Rapid Communications in Mass Spectrometry, 2019), they validated it to cover the parent peptide, four metabolites, and two oxidation products — explicitly, as distinct species requiring their own detection. If an anti-doping laboratory considers the oxidation products worth resolving by name, a supplier’s certificate can reasonably be expected to say something about them.

So the question that separates serious MOTS-c suppliers is narrow and answerable: does the certificate address oxidized species at all?

The three questions a MOTS-c COA must answer separately

Suppliers habitually collapse three independent questions into one percentage.

Question	What it asks	Method	How it should be reported
Identity	Is this MRWQEMGYIFYPRKLR?	Mass spectrometry — LC-MS, ESI-MS, MALDI-TOF	Expected mass vs. measured mass, with observed ions or a deconvoluted neutral mass
Purity	What fraction of the peptide material is the target?	Reverse-phase HPLC, typically 214 nm	Percentage plus the chromatogram
Content	How much actual peptide is in the vial?	Amino acid analysis, nitrogen determination, or quantitative UV	Net peptide content as a percentage of gross weight

What RP-HPLC purity actually tells you

Reverse-phase HPLC separates by hydrophobicity and reports relative peak area — what fraction of the detected signal belongs to the main peak. Three limitations follow directly from that definition:

It is relative, not absolute. A 98% figure means the main peak is 98% of the integrated area, not that the vial is 98% peptide by weight.
It is sensitive to integration choices. Where the analyst draws the baseline, and whether a shoulder is integrated separately or merged into the main peak, changes the number. This is why the chromatogram matters more than the percentage: a visible shoulder on the leading edge of the main peak is exactly what partially-resolved oxidized species look like.
It is blind to anything that does not absorb at the monitored wavelength. Counterions, residual salts, and water contribute nothing to the UV trace and are therefore invisible to the purity figure entirely.

For the full comparison, see HPLC vs. LC-MS: Understanding Peptide Purity and Identity Testing.

What mass spectrometry adds — and what it cannot do

MS measures mass, which HPLC cannot. For MOTS-c that means confirming a measured mass against the expected ≈ 2174.6 Da, and — critically — revealing whether species at ≈ 2190 Da or ≈ 2206 Da are present.

Two honest limitations:

MS alone does not confirm residue order. Two peptides with the same amino acid composition in a different sequence have the same mass. Sequence confirmation requires tandem MS fragmentation or Edman degradation, which most commercial COAs in this market do not include.
A pass/fail stamp is not a result. “Identity: Conforms” tells you a technician made a judgment. A measured mass with observed ions tells you what the instrument saw.

Expected mass spectrometry values

MOTS-c is strongly basic — two arginines, one lysine, plus the free N-terminus — so electrospray typically shows it at multiple charge states. Calculated from the ≈ 2174.6 Da average mass:

Charge state	MOTS-c (≈ 2174.6 Da)	Mono-oxidized (≈ 2190.6 Da)
[M+2H]²⁺	≈ 1088.3 m/z	≈ 1096.3 m/z
[M+3H]³⁺	≈ 725.9 m/z	≈ 731.2 m/z
[M+4H]⁴⁺	≈ 544.7 m/z	≈ 548.7 m/z

These are illustrative average-mass calculations, not reference standards. Monoisotopic values run lower; sodium and potassium adducts add roughly 22 and 38 Da to the singly charged equivalent. Compare against the expected mass stated on the supplier’s own certificate for that product.

Why net peptide content is reported separately

A lyophilized peptide is not pure peptide by weight. It carries bound water, residual salts, and counterions from purification — commonly trifluoroacetate when the final step was RP-HPLC with TFA, or acetate after ion exchange.

MOTS-c has three basic sites available to carry counterions. Across synthetic peptides, net peptide content commonly lands in the 60–90% range of gross vial weight, with the exact figure driven by the basic residue count and the salt form. A theoretical estimate is peptide MW ÷ (peptide MW + bound counterions × counterion MW), with TFA at 114 and acetate at 59. That estimate is a sanity check; the measured figure belongs on the certificate.

There is a downstream reason to care beyond the arithmetic: residual TFA is reported to affect cell and tissue growth in culture at low concentrations, so acetate-salt material or a stated low residual-TFA figure is often preferred for sensitive in-vitro work.

This is why two vials labeled “99% pure” can contain meaningfully different quantities of peptide. Purity describes the composition of the peptide fraction. Content describes how much of the vial is peptide at all. Neither implies the other.

The MOTS-c COA checklist

Hold any candidate for best MOTS-c peptide supplier to this list, lot by lot.

The product is named by full compound name or sequence — “MOTS-c” or MRWQEMGYIFYPRKLR — not a catalog code alone.
The 16-residue sequence appears on the certificate.
An expected mass or molecular formula is stated — ≈ 2174.6 g/mol, C₁₀₁H₁₅₂N₂₈O₂₂S₂.
A measured mass is reported alongside it, with observed ions or a deconvoluted neutral value — not a bare “conforms.”
Oxidized species are addressed explicitly, by percentage, by a statement that none were detected above a threshold, or by a visible chromatogram that lets you judge.
The RP-HPLC chromatogram is included, not only a percentage.
Net peptide content is stated separately from purity, with the method named.
The lot number on the COA matches the lot number on your vial. The single most-skipped check.
The testing laboratory is named, with an analysis date and a report reference you can authenticate.
Manufacture and retest dates are present, and the COA is not years older than the lot.
Storage and light-protection guidance is peptide-specific — for an oxidation-sensitive peptide, generic “store cool and dry” is thin.
Research Use Only status is explicit, not implied.

How to read “third-party tested” claims

“Third-party tested” has no fixed legal meaning in this market. Its value depends entirely on who ran the test and who chose the sample.

Four tiers, weakest to strongest:

Unsupported claim. The phrase appears on the site; no document is attached. This carries no information.
In-house testing presented as third-party. The analysis was run by the manufacturer or an affiliated laboratory. The result may be accurate; nobody independent verified it. Search the lab name against the supplier’s address and ownership.
Independent lab, supplier-selected sample. A genuinely separate laboratory tested material the supplier chose and sent. Meaningfully better than nothing, and the common case — but the supplier controlled the sample.
Independent lab, lot-specific, buyer-verifiable. The certificate ties to the lot you received, names the lab, and carries a report ID you can check with that lab directly. This is the standard worth holding out for.

Four questions that separate the tiers: Who owns the lab? Can the report be authenticated? Does it cover my lot? How old is it?

On ISO/IEC 17025 accreditation

Some analytical laboratories hold ISO/IEC 17025:2017 accreditation, the international standard for the competence of testing and calibration laboratories. Two caveats travel with it.

Accreditation is granted for a defined scope recorded in a published schedule — specific tests, methods, and ranges. A laboratory accredited for one method is not thereby accredited for everything on its price list, so a general “ISO 17025 accredited” badge does not establish that the analysis on your certificate fell inside that scope. Accreditation bodies publish the schedules, and they are checkable.

And accreditation describes the laboratory, not the material. An accredited lab can competently characterize a sample that has nothing to do with the vial on your bench.

On GMP claims

ICH Q7, adopted by FDA as guidance in 2001, is the harmonized GMP standard for active pharmaceutical ingredients; its section 11.4 requires an authentic certificate of analysis for each API batch listing every test, its acceptance limits, and the numerical results. 21 CFR Parts 210 and 211 cover finished drug products.

A facility can run GMP lines for some products and non-GMP lines for others, so “made in a GMP facility” is not “this lot was made under GMP.” And a GMP claim attached to a product labeled research-use-only sits awkwardly with that label. Ask which standard, which inspecting body, and whether documentation covers your lot. Best Peptide Blend Suppliers in 2026 goes further into this.

What lab-tested supplier reviews can and cannot tell you

Reviews are not useless. They are just evidence about a different thing than most readers assume.

Reviews cannot verify purity, identity, or content. A reviewer who did not run the analysis is reporting what a document said, and a reviewer who did run it tested their vial, not yours. Analytical results are lot-specific by nature.

Reviews can tell you about process reliability, which is genuinely worth knowing:

Did the promised documentation actually arrive, or did the buyer have to chase it?
Did the lot number on the COA match the vial, or was a “representative” certificate sent instead?
Could the named testing laboratory be contacted, and did it confirm the report?
Did material arrive with appropriate cold-chain and light protection?
Was appearance consistent across orders — and did anything drift over time?

That last point is the most useful signal reviews offer. A single lot tells you little about a supplier. A pattern of consistent documentation across lots, reported by multiple independent buyers over months, tells you something a one-off analysis cannot.

Read reviews for process, not chemistry. And apply the FTC rule as a filter: if the review site sells the product, or is paid per click, that is disclosed content at best and prohibited content at worst.

A note on search results: MOTS, MOT, and MOTS-c

Searching for MOTS-c suppliers surfaces a predictable amount of noise, because the letter string collides with unrelated technical vocabulary:

MOT testing is the United Kingdom’s annual vehicle roadworthiness inspection. “MOTS suppliers” returns automotive garages.
MOTS in procurement means “Modified Off-The-Shelf,” a contracting category.
Mitochondrial oxidative phosphorylation assays are laboratory test kits that measure mitochondrial respiration. They are not MOTS-c, and the suppliers who sell them are generally not peptide suppliers.

None of these are MOTS-c. The practical filter: a genuine MOTS-c supplier lists the compound by full name or by the sequence MRWQEMGYIFYPRKLR, with a CAS number and a molecular weight. An assay kit vendor lists plates, reagents, and a protocol.

What the published research actually contains

Understanding the evidence base matters for supplier evaluation, because the distance between what the literature reports and what product pages imply is itself a diagnostic.

Study	Model	Reported finding
Lee C, et al. Cell Metab. 2015;21(3):443–454	Mouse, cell culture	Original identification of MOTS-c; reported effects on metabolic homeostasis, insulin sensitivity, and the folate–methionine cycle, with AMPK activation
Reynolds JC, et al. Nat Commun. 2021;12:470	Mouse, human plasma	Reported MOTS-c as exercise-responsive and examined age-related physical decline in mice
Kumagai H, et al. Physiology. 2023	Biochemical	Reported casein kinase 2 as a direct MOTS-c binding partner
Knoop A, Thomas A, Thevis M. Rapid Commun Mass Spectrom. 2019;33(4):371–381	Human plasma, analytical	LC-MS detection method validated to WADA laboratory standards; LOD 100 pg/mL; covers four metabolites and two oxidation products

What does not exist, and this list is as important as the one above:

No FDA approval. MOTS-c is not approved by the U.S. Food and Drug Administration for any indication.
No large randomized controlled trials. The human data consist largely of observational measurements of endogenous MOTS-c, not controlled administration studies.
No established safety profile outside the laboratory. There is no pharmacovigilance body of the kind that supports an approved medicine.
Measurement disagreement in the literature itself. Knoop and colleagues reported that endogenous plasma concentrations given by a commercial ELISA (45.9–218.5 ng/mL in 20 healthy subjects) could not be confirmed by LC-MS, with considerable differences between methods. Published concentration figures for this peptide should be read with the assay in mind.

This section summarizes published findings for research context only. It is not a description of effects in people and contains no guidance on use.

Why this matters when you read a product page. A supplier writing “MOTS-c has been studied for effects on metabolic health” is doing something specific. In its August 2026 warning letters, FDA cited exactly this construction — “Studied for effects on glycemic control and insulin sensitivity” — as evidence that products were intended for human use, notwithstanding research-use-only labels. Outcome-flavored claims are not a marker of scientific sophistication. They are a marker of regulatory exposure.

Regulatory status in 2026

Not an approved drug. MOTS-c is not approved by FDA for any use. Material sold under this name is not equivalent to and is not a substitute for any approved medicine, and no therapeutic claim can lawfully be made for it in the United States.

Recently moved within FDA’s 503A framework. On April 15, 2026, FDA announced it would remove twelve peptides — MOTS-c among them, alongside Semax and BPC-157 — from Category 2 of the 503A bulk drug substances categories, ahead of Pharmacy Compounding Advisory Committee review. Read that carefully: removal from Category 2 is not approval, and it does not by itself make a substance eligible for compounding under section 503A. It means FDA’s prior categorization has been withdrawn pending further evaluation. The status is unresolved, not favorable. Verify the current 503A categories list before relying on any characterization of it, including this one.

“Research use only” is not a shield. Under 21 CFR 201.128, intended use is determined from the objective intent of those responsible for labeling — evidenced by labeling, advertising, and surrounding circumstances. FDA evaluates the net impression of a website as a whole, not the disclaimer at the bottom of it.

Date	Recipients	What FDA cited
Dec. 2024 – Dec. 2025	Summit Research Peptides; Pinnacle Peptides	Website content establishing human-use intent despite research disclaimers
Mar. 31, 2026	Gram Peptides; Prime Sciences; Pink Pony Peptides; Mile High Compounds; PekCura Labs	Outcome claims notwithstanding RUO labeling
Aug. 24, 2026	Peak Performance Peptides; Royal Peptides; NuScience Peptides; Peptide Partners; TXP Innovations	Unapproved new drugs; RUO disclaimers rejected on a net-impression basis. Cited dosing guidance, reconstitution calculators, and bacteriostatic water sold alongside injectables

What this means when you choose a supplier. Setting aside whether a vendor’s conduct is lawful — that is FDA’s question — the procurement question is narrower: a supplier operating in the posture FDA has repeatedly cited may face enforcement that interrupts availability of material your work depends on, mid-study. Continuity of supply is a real evaluation criterion.

Anti-doping. MOTS-c is widely reported to be prohibited in sport, and a doping-control detection method validated to WADA’s International Standard for Laboratories has existed since 2019. WADA’s Prohibited List is revised annually and includes catch-all provisions that can capture substances not named individually. Anyone whose work touches athlete populations should verify the current list directly rather than relying on any secondary summary, including this one.

State law and importation. Several states regulate research chemical sales separately, and customs authorities may detain shipments of unapproved drugs. Institutions and individual researchers are responsible for confirming the rules that apply to them.

This section is general information, not legal advice. Peptide regulation moved repeatedly across 2025 and 2026. Verify current status on FDA’s own pages before relying on anything described here.

Red flags on a MOTS-c listing or certificate

Each is better read as a documentation gap than as proof of misconduct — the record is insufficient to verify the claim, which warrants a question.

No sequence printed, or a sequence of the wrong length.
No mention of oxidized species anywhere on a certificate for a peptide with three oxidation-prone residues.
RP-HPLC purity with no identity result from a second method.
Purity quoted to implausible precision — “99.98%” — with no chromatogram.
A chromatogram showing an unexplained shoulder on the leading edge of the main peak.
No lot number, or a lot number that does not match your vial.
The same COA image appearing across multiple products or multiple years.
An unnamed laboratory, or a named lab with no verifiable report ID.
A certificate that is a photograph or low-resolution screenshot rather than a document.
Net peptide content absent, or purity presented as though it were content.
Generic storage guidance with no light protection mentioned.
Compounding-pathway language on a research-use-only product page.
Dosing guidance, reconstitution calculators, benefit claims, testimonials, or injection supplies offered alongside the vial.

How Peptides Exchange documents this material

Our MOTS-c is supplied in 10 mg and 40 mg research vials, and the lot certificate is published on our Certificates of Analysis page — testing by Freedom Diagnostics using HPLC-UV and LC-MS, with the submitted sample, methods, and reported results identified on the report.

Apply the checklist above to that certificate rather than taking the method on faith. Specifically: confirm the lot number matches the vial you receive, check that a measured mass accompanies the expected mass, and look at what the chromatogram shows around the main peak. If a current lot’s certificate does not state something on the checklist, ask us for it — that request is reasonable, and a supplier’s response to it is itself a data point.

All products are supplied for laboratory research use only and are not for human or animal consumption.

A ten-step evaluation sequence

Confirm the listing identifies MOTS-c by full name or sequence, not a catalog code, and that it is a peptide rather than an assay kit.
Check that CAS number, molecular formula, and molecular weight agree with one another.
Request the current lot’s COA — not a representative or sample certificate.
Match the lot number on the COA to the lot number on the vial.
Review the RP-HPLC purity figure and the chromatogram, looking specifically at the leading edge of the main peak.
Confirm a separate identity result from mass spectrometry, with a measured value.
Check whether oxidized species are addressed, by percentage or by an explicit statement.
Check net peptide content, stated separately from purity, with the method named.
Verify the laboratory name, analysis date, and report reference, and authenticate the report if the lab offers verification.
Repeat for every new lot. A supplier that passed last quarter has not thereby passed today — and for an oxidation-sensitive peptide, lot-to-lot consistency is the thing you are actually buying.

Frequently asked questions

What does MOTS-c stand for?

Mitochondrial Open reading frame of the Twelve S rRNA type-c. The name describes where the coding sequence sits in the mitochondrial genome — within the MT-RNR1 (12S rRNA) gene. It is not the name of an assay or a test method.

Who is the best MOTS-c peptide supplier in 2026?

We do not publish a ranking, and we would treat any such list with suspicion when the publisher sells the product. The answerable question is whether a supplier provides a lot-specific certificate that names the compound and sequence, states an expected mass, reports a matching measured mass from an identifiable laboratory, addresses oxidized species, and gives net peptide content separately from purity. A supplier that does all of that is verifiable. One that does not is asking for trust it has not evidenced. Our own MOTS-c certificate is published for exactly that scrutiny.

Why does oxidation matter for MOTS-c quality?

MOTS-c contains two methionine residues and one tryptophan in a 16-residue chain. All three oxidize readily on exposure to oxygen, light, or trace metals. Each oxidation event adds roughly 16 Da, producing chemically distinct species that generally elute earlier than the parent peptide on reverse-phase HPLC. Because oxidized peaks can sit close to the main peak, integration choices can fold them into a high-looking purity figure.

What should a MOTS-c COA show?

The compound name and the 16-residue sequence, an expected mass or molecular formula, a measured mass, RP-HPLC purity with a chromatogram, a statement on oxidized species, net peptide content with its method, the lot number matching your vial, the testing laboratory, an analysis date, and a report reference number.

What is the molecular weight of MOTS-c?

Approximately 2174.6 g/mol average mass, formula C₁₀₁H₁₅₂N₂₈O₂₂S₂, CAS 1627580-64-6. A mono-oxidized species would appear roughly 16 Da higher.

Why do two MOTS-c vials with the same purity contain different amounts of peptide?

Because purity and content measure different things. Purity is the fraction of the peptide material that is the target molecule. Content is the fraction of the vial’s gross weight that is peptide at all. Counterions, bound water, and residual salts make up the difference, and they vary by salt form and manufacturing process.

Can supplier reviews confirm MOTS-c purity?

No. Analytical results are lot-specific, and a reviewer tested their vial, not yours. Reviews are useful evidence about process reliability — whether documentation arrived, whether lot numbers matched, whether the testing lab could be reached — not about the chemistry of your material.

Are mitochondrial oxidative phosphorylation assay suppliers the same as MOTS-c suppliers?

No. Those vendors sell test kits that measure mitochondrial respiration. MOTS-c is a synthetic peptide. The names collide in search results; the products are unrelated.

Is MOTS-c FDA approved?

No. It is not approved for any use in the United States. In April 2026 FDA announced the removal of MOTS-c and eleven other peptides from Category 2 of its 503A bulk drug substances categories ahead of advisory committee review, which leaves its compounding status unresolved rather than approved. Research-use-only material has never been reviewed or approved by FDA for any use.

For research and laboratory use only. Not for human or animal consumption. Peptides Exchange is a chemical supplier. It is not a compounding pharmacy as defined under section 503A of the Federal Food, Drug, and Cosmetic Act, and not an outsourcing facility as defined under section 503B. Nothing in this article is medical, legal, or regulatory advice, and nothing in it describes or recommends use of any substance in humans or animals.

Sources

Chemistry and primary literature

Analytical and manufacturing standards

Regulatory

Related reading in our Research Library

Best MOTS-c Peptide Suppliers in 2026: Third-Party Tested Vendors, COAs, and How to Read Lab-Tested Supplier Reviews